ARCH Venture Management as of Dec. 31, 2025
Portfolio Holdings for ARCH Venture Management
ARCH Venture Management holds 9 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Maze Therapeatics (MAZE) | 26.2 | $171M | 4.1M | 41.43 | |
| Beam Therapeutics (BEAM) | 19.3 | $126M | 4.5M | 27.72 | |
| Rapport Therapeutics (RAPP) | 17.4 | $113M | 3.7M | 30.34 | |
| Lyell Immunopharma Com New (LYEL) | 13.0 | $85M | 2.8M | 30.78 | |
| Vir Biotechnology (VIR) | 12.0 | $78M | 13M | 6.03 | |
| Erasca (ERAS) | 6.3 | $41M | 11M | 3.72 | |
| Gossamer Bio (GOSS) | 3.8 | $25M | 8.1M | 3.10 | |
| 10x Genomics Cl A Com (TXG) | 1.8 | $12M | 738k | 16.31 | |
| Q32 Bio (QTTB) | 0.2 | $1.1M | 321k | 3.32 |
